Dr. Silverman's distinguished career in chemistry and drug discovery is marked by significant contributions to both academia and industry. His academic journey began with a bachelor's degree in Chemistry from Pennsylvania State University, followed by a PhD in Organic Chemistry from Harvard University under the guidance of David Dolphin. Postdoctoral research at Brandeis University with Robert Abeles further honed his expertise in enzymology. Currently, as the Patrick G. Ryan/Aon Professor of Chemistry at Northwestern University, Dr. Silverman leads a dynamic research group focused on diseases of the central nervous system and cancer, blending fundamental research with translational applications.

Bringing over fifty years of research and pharmaceutical development experience to Radyus as a member of the Scientific Advisory Board, Dr. Silverman's impact extends beyond academia. He is renowned for his pivotal role in discovering Lyrica® (pregabalin), a widely used medication for fibromyalgia, neuropathic pain, epilepsy, and anxiety. Additionally, his inventions include CPP-115, progressing through clinical trials, and OV329 and NU-9 (AKV9) for movement disorders and ALS, respectively. Recognized with prestigious awards like the Perkin Medal and induction into the Medicinal Chemistry Hall of Fame, Dr. Silverman's 396 peer-reviewed articles and 130 patents reflect his commitment to advancing therapeutic options. As the founder of Akava Therapeutics, he continues to pioneer first-in-class small molecule therapeutics targeting neurodegenerative diseases and cancers, driven by a mission to address unmet medical needs and improve patients' quality of life.